Archive for the ‘Treatment’ Category

Are COVID Shots Fueling More Dangerous Mutations?

https://articles.mercola.com/sites/articles/archive/2021/08/12/covid-shots-drive-mutations.aspx  Video in link

If Youtube censors this “must see” video, which it probably will, go to Odysee here:  https://odysee.com/@whatsherface:2/variants:d

Are COVID Shots Fueling More Dangerous Mutations?

Analysis by Dr. Joseph MercolaFact Checked

August 12, 2021

STORY AT-A-GLANCE

  • When vaccines that don’t provide robust immunity are overused, they allow viruses to mutate in potentially hazardous ways. COVID variants with measurably different behavior emerged in mid-December 2020, which coincides with the rollout of the first COVID shots
  • While variants were identified in various areas before the shots were introduced in those same regions, vaccine makers were conducting large-scale trials on thousands of people in those areas well before the shots became available to the public, and before variants were detected
  • The COVID shots do not prevent infection or transmission, hence the variants created inside vaccinated individuals will spread. This hypothesis was confirmed in a 2015 study, which found that “imperfect vaccination can enhance the transmission of highly virulent pathogens”
  • Research shows fully vaccinated individuals who develop breakthrough infections with the Delta variant have the same viral loads as unvaccinated individuals infected with this virus, hence both groups can spread the infection to the same degree
  • Data from the U.S. Centers for Disease Control and Prevention show 74% of COVID-19 diagnoses in Barnstable County, Massachusetts, between July 6 through July 25, 2021, and 80% of hospitalizations, were among the fully vaccinated

Will mass injections against COVID-19 encourage the mutation of more dangerous versions of SARS-CoV-2? In the video above, WhatsHerFace questions why the U.K. government is procuring 6 million pounds’ worth of body bags, or “temporary body storage,” even as government officials announce that the current vaccination rate has “created a protective wall” against the infection.1

If that’s true, why are they expecting an “excess death scenario” requiring massive numbers of body bags? The procurement agreement will remain in effect for a period of four years. Does the U.K. government know something they’re not sharing with the public?

Have they peeked at the actual science and realized that mass vaccination during an active pandemic might encourage mutations that evade vaccine-induced defenses, or that the gene-modifying injections might render the vaccinated more susceptible to serious illness and death through a mechanism known as antibody-dependent enhancement (ADE) or the more descriptive term, paradoxical immune enhancement (PIE)?

Where Are the Variants Coming From, and Why Now?

WhatsHerFace highlights some of the answers given by health professionals on social media when asked why no problematic variants emerged during the first year, when no COVID injections were available, and only popped up after the mass injection campaign started.

According to one such answer, “Our surveillance sucked in the beginning and it takes time for variants to come about but once they come they become rampant.” Interestingly, as noted in a February 15, 2021, article in The Conversation,2 variants with “measurably different behavior” did not emerge until mid-December 2020, which just so happens to be the exact time at which the first COVID shots were rolled out.

Fact checkers have tried to debunk any connection between COVID shot rollouts and the emergence of variants by showing that variants were identified in various areas before the shots were introduced in those same regions. However, as noted by WhatsHerFace, vaccine makers were conducting large-scale trials in those areas well before the shots became available to the public.

For example, Pfizer enrolled more than 46,000 participants in the U.S., Argentina, Brazil, South Africa, Germany and Turkey,3 and Oxford/AstraZeneca injected 23,000 participants in the U.K., Brazil and South Africa.

“Now this is very interesting,” WhatsHerFace says, “because you’ll actually find that each of the areas where variants first emerged just happen to be the same countries where the trials took place.”

The Backstory of the Delta Variant

The Delta variant (B.1.617.2) was initially identified in India December 1 and 11, 2020. While the COVID jabs were not rolled out in India until mid-January 2021, Phase 3 trials for Biotech’s Covaxin were initiated in Bharat, India, November 16, 2020. By December 22, 2020, 22,500 volunteers had received the jab.

On a side note, the Indian government released Covaxin to the public before Phase 3 trials were completed and in the absence of any safety or efficacy data. According to some vaccinologists, the emergence of potentially more problematic variants following mass vaccination rollouts during an active pandemic is precisely what you’d expect.

Dr. Geert Vanden Bosche,4 whose resume includes work with GSK Biologicals, Novartis Vaccines, Solvay Biologicals and the Bill & Melinda Gates Foundation, published an open letter5 to the World Health Organization, March 6, 2021.

In the letter, Bosche warned that implementing a global mass vaccination campaign during the height of the pandemic could create an “uncontrollable monster” where evolutionary pressure will force the emergence of new and potentially more dangerous mutations.

“There can be no doubt that continued mass vaccination campaigns will enable new, more infectious viral variants to become increasingly dominant and ultimately result in a dramatic incline in new cases despite enhanced vaccine coverage rates. There can be no doubt either that this situation will soon lead to complete resistance of circulating variants to the current vaccines,” Bossche wrote.6

‘Leaky’ Vaccines Promote Mutations

In short, when vaccines that don’t provide robust immunity are overused, they allow viruses to mutate in potentially hazardous ways. When you overuse an antibiotic that fails to eradicate the bacteria, antibiotic-resistant bacteria are allowed to flourish.

In the same way, overuse of a vaccine that doesn’t provide immunity can allow the virus to mutate inside vaccinated individuals into variants that evade vaccine-induced immunity.

And, as we already know, the COVID shots do not prevent infection or transmission, hence the variants created inside vaccinated individuals will spread, attacking both vaccinated and unvaccinated alike. This hypothesis was confirmed in a 2015 study7 in PLOS Biology, which found that “imperfect vaccination can enhance the transmission of highly virulent pathogens.” As explained by the authors:8

“There is a theoretical expectation that some types of vaccines could prompt the evolution of more virulent (‘hotter’) pathogens. This idea follows from the notion that natural selection removes pathogen strains that are so ‘hot’ that they kill their hosts and, therefore, themselves.

Vaccines that let the hosts survive but do not prevent the spread of the pathogen relax this selection, allowing the evolution of hotter pathogens to occur. This type of vaccine is often called a leaky vaccine. When vaccines prevent transmission, as is the case for nearly all vaccines used in humans, this type of evolution towards increased virulence is blocked.

But when vaccines leak, allowing at least some pathogen transmission, they could create the ecological conditions that would allow hot strains to emerge and persist.

This theory proved highly controversial when it was first proposed over a decade ago, but here we report experiments with Marek’s disease virus in poultry that show that modern commercial leaky vaccines can have precisely this effect: they allow the onward transmission of strains otherwise too lethal to persist.

Thus, the use of leaky vaccines can facilitate the evolution of pathogen strains that put unvaccinated hosts at greater risk of severe disease.”

This research was reported in a number of mainstream media publications, including Live Science,9 Newsweek10 and National Geographic.11 Quanta Magazine also took a deep dive into it in May 2018, closing the article with the following observation:12

“… the most crucial need right now is for vaccine scientists to recognize the relevance of evolutionary biology to their field. Last month, when more than 1,000 vaccine scientists gathered in Washington, D.C., at the World Vaccine Congress, the issue of vaccine-induced evolution was not the focus of any scientific sessions.

Part of the problem, [disease ecologist Andrew] Read says, is that researchers are afraid: They’re nervous to talk about and call attention to potential evolutionary effects because they fear that doing so might fuel more fear and distrust of vaccines by the public …”

The COVID shots, which do not make you immune against the virus but rather only lessen symptoms of infection, are a perfect example of leaky vaccines that can allow the virus to mutate within the mildly ill host, who then transmits the mutated virus to others. In this way, the shots can fuel a never-ending chain of outbreaks.

NPR Highlights How Vaccines Drive Viral Evolution

In a February 9, 2021, article,13 NPR highlighted this risk, stating that “vaccines could drive the evolution of more COVID-19 mutants.” According to NPR science correspondent Richard Harris, “the virus is always mutating. And if one happens to produce a mutation that makes it less vulnerable to the vaccine, that virus could simply multiply in a vaccinated individual.”

Simply having a virus mutating inside you isn’t necessarily dangerous, however. The viral load also plays an important role in determining how potentially dangerous a vaccinated individual who carries a mutation might be. If your viral load is low, the risk of you transmitting the mutated virus to others is also low. If your viral load is high, then the risk of transmission increases accordingly.

When it comes to the Delta variant, there’s bad news for those who have received one or more COVID shots, as research14 shows fully vaccinated individuals who develop breakthrough infections with the Delta variant have the same viral loads as unvaccinated individuals who are infected with this virus. As reported by Reuters August 2, 2021:15

“Among people infected by the Delta variant of the coronavirus, fully vaccinated people with ‘breakthrough’ infections may be just as likely as unvaccinated people to spread the virus to others, new research suggests. The higher the amount of coronavirus in the nose and throat, the more likely the patient will infect others.

In one Wisconsin county, after Delta became predominant, researchers analyzed16 viral loads on nose-and-throat swab samples obtained when patients were first diagnosed. They found similar viral loads in vaccinated and unvaccinated patients, with levels often high enough to allow shedding of infectious virus.

‘A key assumption’ underlying current regulations aimed at slowing COVID-19 transmission ‘is that those who are vaccinated are at very low risk of spreading the virus to others,’ said study coauthor Katarina Grande of Public Health Madison & Dane County in Madison, Wisconsin.

The findings, however, indicate ‘that vaccinated people should take steps to prevent the spread of the COVID-19 virus to others,’ she added.”

Lambda Variant Shows Signs of Vaccine Resistance

The latest coronavirus on the block is Lambda, which was first identified in Peru. It’s now spreading through South America. Like the Delta variant, Lambda is more infectious than the original SARS-CoV-2 virus. Unlike Delta, it appears more resistant to vaccine-induced antibodies.

According to Reuters,17 three spike protein mutations “help it resist neutralization by vaccine-induced antibodies.” While some claim the emergence of Delta and Lambda is justification for a third booster shot, Rockefeller University researchers point out that a third dose might raise the number of antibodies, but it won’t improve their ability to neutralize viruses.18,19

If a third dose can’t neutralize any of the variants any better than two doses, then we’re back at the beginning of this vicious cycle where imperfect neutralization drives additional mutation.

The Rockefeller University paper also highlights the superior protection offered by natural immunity, which is what you get after you’ve recovered from an infection. According to the authors,

“memory antibodies selected over time by natural infection have greater potency and breadth than antibodies elicited by vaccination.”

For transparency, one of the coauthors, Michel Nussenzweig, told Reuters that if an updated injection capable of protecting against one or more specific variants were to become available, “then that would be the choice.”

I mention that, because the competing interest statement on that paper reveals the Rockefeller University “has filed a provisional patent application in connection with this work … (US patent 63/021,387). The patent has been licensed by Rockefeller University to Bristol Meyers Squib.”

An identical competing interest statement can also be found on other recent papers, including a preprint paper20 titled “Development of Potency, Breadth and Resilience to Viral Escape Mutations in SARS-CoV-2 Neutralizing Antibodies.”

At the time of writing, I got nothing but error messages when trying to access the U.S. patent office to confirm what U.S. patent 63/021,387 might be, but based on the papers bearing this competing interest statement, it sounds like the Rockefeller University might be patenting a new COVID shot against variants.

First COVID Shots Appear Ineffective Against Newer Variants

At the same time that Moderna and Pfizer raise prices on their individual COVID shots by 10% and 25% respectively,21 evidence of their ineffectiveness continues to mount.

In a July 30, 2021, report,22 Sharyl Attkisson cited data23 from the U.S. Centers for Disease Control and Prevention, which show that 74% of COVID-19 diagnoses in Barnstable County, Massachusetts, between July 6 through July 25, 2021, and 80% of hospitalizations, were among the fully vaccinated.

“The report contradicts multiple false reports that have claimed the vaccines are ‘100% effective’ in preventing hospitalization,” Attkisson writes.24

“It also contradicts false reports that have implied vaccinated people are not spreading Covid-19. According to CDC, the fully vaccinated are showing just as high of a ‘viral load’ as unvaccinated people who get infected.

CDC published new data25 on the topic in its weekly report. It says that most of the identified cases of Covid-19 in a Barnstable County, Massachusetts, town, in July (74%) were among fully vaccinated people.

Most, but not all, had the Delta variant. Additionally, four of five hospitalized patients were fully vaccinated. Only one was not fully vaccinated. Today, CDC also acknowledged that Covid-19 viral load is ‘similarly high’ in both vaccinated and unvaccinated people. That’s a result, say officials, of the Delta variant.

From the start, virologists said that there would be natural variants to Covid-19. They also accurately predicted that effectiveness of Covid-19 vaccines would wear down in a matter of months, not years. Now, CDC is confirming that the current Covid-19 vaccines are not working effectively against Covid-19.

In contrast, the millions of Americans who have fought off Covid-19 infections, either with or without symptoms, are proving to have greater and longer lasting immunity, so far, than those who have been vaccinated. That, too, was predicted by virologists.”

Americans are now told the Delta variant is a pandemic among the unvaccinated, even though the data doesn’t support this claim. The CDC appears to be trying to prop up this narrative by not reporting breakthrough infections in vaccinated individuals unless they are hospitalized or die.

Even then, they acknowledge them only if they have a positive PCR test run at a cycle threshold (CT) below 28,26 whereas unvaccinated people are still tested at a CT of 40 or above. The higher the CT, the greater the chance of a false positive.

Israeli Data Show Waning Effectiveness of Pfizer Shot

Israel is now recommending a third booster shot for people over the age of 60, as data27 show the Pfizer injection is only 39% effective (relative risk reduction) against the Delta variant, down from 64% relative effectiveness two weeks earlier.

As of August 2, 2021, 66.9% of Israelis had received at least one dose of Pfizer’s injection; 62.2% had received two doses.28 A day earlier, August 1, director of Israel’s Public Health Services, Dr. Sharon Alroy-Preis, announced half of all COVID-19 infections were among the fully vaccinated.29 Signs of more serious disease among fully vaccinated are also emerging, she said, particularly in those over the age of 60.

Alternative Treatments

In closing, remember there are several different treatment protocols for COVID-19 that appear just as effective for variants as for the original virus, including the following:

____________________

For more:

Category:

Activism, Treatment, vaccines, Viruses

Double-Blind Study Shows Ivermectin Reduces Disease Duration & Infectiousness

https://m-jpost-com.cdn.ampproject.org/c/s/m.jpost.com/health-science/israeli-scientist-says-covid-19-could-be-treated-for-under-1day

By MAAYAN JAFFE-HOFFMAN

AUGUST 2, 2021 21:01

Double-blind study shows ivermectin reduces disease’s duration and infectiousness • FDA and WHO caution against its use

Ivermectin, a drug used to fight parasites in third-world countries, could help reduce the length of infection for people who contract coronavirus for less than a $1 a day, according to recent research by Sheba Medical Center in Tel Hashomer.
Prof. Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba, conducted a randomized, controlled, double-blinded trial from May 15, 2020, through the end of January 2021 to evaluate the effectiveness of ivermectin in reducing viral shedding among nonhospitalized patients with mild to moderate COVID-19.
Ivermectin has been approved by the US Food and Drug Administration since 1987. The drug’s discoverers were awarded the 2015 Nobel Prize in medicine for its treatment of onchocerciasis, a disease caused by infection with a parasitic roundworm.
Over the years, it has been used for other indications, including scabies and head lice. Moreover, in the last decade, several clinical studies have started to show its antiviral activity against viruses ranging from HIV and the flu to Zika and West Nile.  (See link for article)
____________________
**Comment**
The study found in MedRxiv, a health-research sharing site, has not yet been peer reviewed.  The study found:
  • Approx. 72% of the Ivermectin group tested negative and 13% were infectious after day six
  • 50% of the placebo group tested positive and 50%, almost 4 times as many, were infectious after day six
  • 5 patients were referred to hospitals, 4 of them were in the placebo group
  • One hospitalized patient complained of shortness of breath, continued on ivermectin and was sent back to the hotel a DAY later in good condition
“Our study shows first and foremost that ivermectin has antiviral activity,” Schwartz said. “It also shows that there is almost a 100% chance that a person will be noninfectious in four to six days, which could lead to shortening isolation time for these people. This could have a huge economic and social impact.”
The study author points out that while this study did not address ivermectin as a prophylactic, or address hospitalization reduction, other studies have shown such evidence.
Other studies have shown:
  • 27 studies demonstrate ivermectin’s ability to prevent COVID
  • a recent review found ivermectin reduced death by 75%

Please see:  

isummary

Interestingly, ivermectin is on the WHO’s list of essential medicines yet an Israeli professor states there’s significant risks with it and that ‘caution should be used on a virus that the vast majority of the public will recover from without treatment.’  He didn’t bother to mention anything about fast-tracked experimental “vaccines” that thousands have been maimed and killed from and that experts are warning against.
To date the WHO is not supporting any trials to determine ivermectin’s viability.
Researchers in other places worldwide began looking into the drug at around the same time. But when they started to see positive results, no one wanted to publish them, Schwartz said.
“There is a lot of opposition,” he said. “We tried to publish it, and it was kicked away by three journals. No one even wanted to hear about it. You have to ask how come when the world is suffering.”
“This drug will not bring any big economic profits,” and so Big Pharma doesn’t want to deal with it, he said.
The article points out that some of the loudest opposition has come from Merck, the manufacturer of ivermectin since the 80’s.  Merck was peddling COVID vaccines until it was discovered “the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines.”  Now it’s peddling molnupiravir, which raked in 1.2 BILLION from a deal with the U.S. government.  It is currently in a phase 3 clinical trail.  So why make pennies when you can make BILLIONS?
For more:

Category:

research, Treatment, vaccines, Viruses

Resolving Chronic Viruses Through Immune Modulation With Dr. Frank Shallenberger

https://www.betterhealthguy.com/episode148  Go Here for written transcript

Episode #148: Resolving Chronic Viruses Through Immune Modulation with Dr. Frank Shallenberger, MD

Updated: July 14 2021

Why You Should Listen

In this episode, you will learn about how to resolve chronic viruses through immune modulation.

Watch The Show

About My Guest

My guest for this episode is Dr. Frank Shallenberger.  Frank Shallenberger, MD has been practicing medicine since 1973 and has been a pioneer in alternative and integrative medicine since 1978.  He is one of only 16 physicians in Nevada that are licensed both in conventional medicine as well as alternative and homeopathic medicine; allowing him to integrate the best of both approaches for optimal results.  Dr. Shallenberger has revolutionized the practice of anti-aging and preventive medicine by developing a method to measure mitochondrial function and oxygen utilization.  He has written two popular books describing this method: “The Type 2 Diabetes Breakthrough” and “Bursting With Energy” and has authored numerous papers in the international peer reviewed literature on ozone therapy and oxygen utilization.  He is also the editor of Second Opinion alternative medical newsletter.  He is the developer of Prolozone®, an injection technique that has been shown to regenerate damaged joints, herniated discs, and degenerated joints, tendons, and soft tissues.  He published the first paper on Prolozone Therapy in the Journal of Prolotherapy entitled “Prolozone – Regenerating Joints and Eliminating Pain”.

Key Takeaways

  • What is a virus? Do they contribute to disease?
  • Should the focus be on killing or on immune modulation?
  • Can some viruses be health-promoting?
  • Can antivirals be helpful in dealing with chronic viruses?
  • What is the role of Th1 and Th2 in response to chronic viruses?
  • What are some of the factors that lead to Th2 dominance?
  • Where do antibodies come into the discussion? Are high IgG levels relevant?
  • How do “factories” and “missiles” help to explain the situation with chronic viruses?
  • How big of a foe is EBV?
  • Does the body itself produce ozone?
  • Can ozone help to address both the “factories” and the “missiles”?
  • What are some top “missile defense” tools?
  • How might NK cells be stimulated in shifting the system towards Th1?
  • How might medicinal mushrooms be helpful?
  • Can melatonin be immune-modulating?
  • How might hydrocortisone be helpful in addressing chronic viruses?
  • Is it important to address parasites before downregulating Th2 response?
  • How might immune tolerance tools like LDI be helpful in balancing the immune response?
  • In chronic illness, would more ozone passes be less often or less passes more often be more effective?

Connect With My Guest

http://AntiAgingMedicine.com

_____________________

For more:

Category:

Treatment, Viruses

US Health Officials Warn a Lesser-Known Tick-Borne Infection is On The Up

https://www.iflscience.com/health-and-medicine/on-top-of-lyme-disease-a-lesserknown-tickborne-infection-is-on-the-up/

US Health Officials Warn A Lesser-Known Tick-Borne Infection Is On The Up

By Tom Hale

07 JUL 2021

A little-known and rare tick-borne disease is on the rise in the US. Known as anaplasmosis, the bacterial disease is spread to people by tick bites, primarily from the blacklegged tick (Ixodes scapularis) and the western blacklegged tick (Ixodes pacificus), two species associated with the better-known infection of Lyme disease. 

Health officials in New York’s Onondaga County recently reported an unexpected case of anaplasmosis in Central New York. They also explained that recent years have seen an uptick (excuse the pun) of cases of this once-rare disease in the area. While a total of three cases were reported in Onondaga County from 2015 to 2020, there have been six reported cases so far this year. 

“In New York state, the disease is spread by the blacklegged tick (Ixodes scapularis), which is the same type of tick that typically spreads Lyme disease,” Dr Indu Gupta, health commissioner of Onondaga County, said in a statement. “If we are diligent in practicing the same prevention measures we’ve learned to prevent Lyme disease, we are protecting ourselves from other tickborne diseases including anaplasmosis.” 

(See link for article)

____________________

**Comment**

The US Centers for Disease Control and Prevention (CDC) suggests a similar rise of anaplasmosis is being seen across the country.

The article states that if you see a rash, get to your doctor.  (Many never get a rash and are still infected)

I would state get to your doctor for ANY known tick-bite and request prophylactic treatment.

It is widely known and accepted that prompt diagnosis and treatment is crucial and if treatment is delayed, Anaplasmosis can cause severe illness involving:

  • respiratory failure
  • bleeding problems
  • organ failure
  • death

Treatment for Anaplasmosis is doxycycline which has the advantage of treating numerous tick borne illnesses such as:

  • Lyme (borrelia)
  • Ehrlichia, Anaplasma
  • Q Fever
  • Rocky Mountain Spotted Fever

ILADS states the downside is that Doxy causes significant sun sensitization, can be hard on the stomach, and the usual dosing may not reach therapeutic levels. 

Recent data suggests that treatment may not clear organisms in animals.

Category:

Activism, Anaplasmosis, Treatment

What is Borrelia miyamotoi?

https://danielcameronmd.com/what-is-borrelia-miyamotoi/

WHAT IS BORRELIA MIYAMOTOI?

What is Borrelia miyamotoi

What is Borrelia miyamotoi? This tick-borne illness, transmitted by deer ticks, is believed to be underrecognized and a growing concern, as studies indicate a B. miyamotoi infection may be as common as anaplasmosis and babesiosis. Researchers randomly tested 250 individuals living in Manitoba, Canada and found that 10% were seropositive for B. miyamotoi. [1]

By 

Borrelia miyamotoi (B. miyamotoi) was first reported in the United States in 2013 but has become increasingly more common.  The tick-borne illness can be transmitted by the same tick that carries Borrelia burgdorferi, the Lyme disease pathogen. In their article, Della-Giustina and colleagues² address the question, “What is Borrelia miyamotoi?” and concerns surrounding this growing threat.

Where is B. miyamotoi found?

Borrelia miyamotoi (B. miyamotoi) can be found in various ticks including the deer tick. It has been detected in ticks located in the northeastern and northern Midwestern United States, California, Europe, and Asia.

What stage of deer ticks transmit B. miyamotoi?

Borrelia miyamotoi can be transmitted from all stages of a tick including the larval stage. The larval tick can harbor and transmit B. miyamotoi by passing the pathogen from the parent to the offspring, a process called transovarial transmission.

How fast can B. miyamotoi be transmitted?

Quickly, according to the authors.  “B. miyamotoi can be transmitted 10% of the time within the first 24 hours of attachment, increasing steadily to reach 73% for a complete feeding.  Thus, transmission of B. miyamotoi is more rapid than transmission of B. burgdorferi.”²

Symptoms of B. miyamotoi

The symptoms that have been described include fever, malaise, headache, and myalgias.  Some cases present with an elevated liver test, low white count and abnormal liver tests that have been described in Anaplasmosis, another tick-borne illness.  Only 11% of patients presented with an erythema migrans rash, according to findings from a case series.

Making the diagnosis

It can be difficult to diagnose B. miyamotoi.  “No test specific to B. miyamotoi has been approved by the United States Food and Drug Administration as of October 2020,” the authors explain.

“The most specific test currently available in several public health and commercial laboratories is polymerase chain reaction (PCR) testing of blood or cerebrospinal fluid for the B. miyamotoi GlpQ enzyme.”

“Serologic testing of B. miyamotoi IgM and IgG antibodies is possible by a few commercial laboratories.” Unfortunately, it can be hard to interpret these tests, as they may cross-react to other spirochetes.  (The authors did not address the risk of cross reactions.)

“One test using this approach, the TBD serochip, is an array-based assay testing for 8 different tick-borne diseases, including B. miyamotoi. Developed in 2018, it is promising but has not yet become widely available.”

Treatment of B. miyamotoi 

There are no evidence-based trials to determine the best treatment for B. miyamotoi. Doxycycline has been suggested, as Lyme disease patients have improved with doxycycline.  “In vitro analysis has shown the susceptibility of B. miyamotoi to ceftriaxone, azithromycin, and doxycycline, with resistance to amoxicillin,” the authors explain.

Prophylactic treatment

Since B. miyamotoi can be transmitted rapidly, it may be prudent to consider prophylactic antibiotic treatment immediately, even if the tick has not been attached for 24 to 36 hours.

“Understanding this more rapid transmission of infection of B. miyamotoi may be a consideration in determining prophylactic treatment for tick bites with a shorter time of attachment in endemic areas for B. miyamotoi.”

Related Articles:

Could Borrelia miyamotoi infections explain persistent symptoms in Lyme disease patients?

C6 peptide test may indicate Borrelia miyamotoi infection

The best antibiotics to treat Borrelia miyamotoi?

References:
  1. Kadkhoda K, Dumouchel C, Brancato J, Gretchen A, Krause PJ. Human seroprevalence of Borrelia miyamotoi in Manitoba, Canada, in 2011-2014: a cross-sectional study. CMAJ Open. 2017;5(3):E690-E693.
  2. Della-Giustina D, Duke C, Goldflam K. Underrecognized Tickborne Illnesses: Borrelia Miyamotoi and Powassan Virus. Wilderness Environ Med. Jun 2021;32(2):240-246. doi:10.1016/j.wem.2021.01.005

____________________

**Comment**

I’m always extremely skeptical of ALL information given on transmission times as reality has shown a far different picture.  For more on this:  https://madisonarealymesupportgroup.com/2017/04/14/transmission-time-for-lymemsids-infection/   Important to note: minimum transmission time has never been determined and reality shows it can happen within a few hours.  Certain coinfections can happen within minutes.

Since Borrelia miyamotoi is not a reportable illness to the CDC, no one has any clue about prevalence but reports are coming in continually that it’s highly likely to be a much bigger problem than ‘authorities’ believe.

It was recently discovered that:

Category:

Borrelia Miyamotoi (Relapsing Fever Group), research, Testing, Ticks, Transmission, Treatment